



HAL
open science

GenIDA, a participatory patient registry for genetic forms of intellectual disability provides detailed caregiver reported information on 237 individuals with Koolen-de Vries syndrome

Florent Colin, Pauline Burger, Timothée Mazzucotelli, Axelle Strehle, Joost Kummeling, Nicole Collot, Elyette Broly, Angela T. Morgan, Kenneth A. Myers, Agnès Bloch-Zupan, et al.

► **To cite this version:**

Florent Colin, Pauline Burger, Timothée Mazzucotelli, Axelle Strehle, Joost Kummeling, et al.. GenIDA, a participatory patient registry for genetic forms of intellectual disability provides detailed caregiver reported information on 237 individuals with Koolen-de Vries syndrome. *Genetics in Medicine Open*, 2023, 1 (1), pp.100817. 10.1016/j.gimo.2023.100817 . hal-04199652

HAL Id: hal-04199652

<https://hal.science/hal-04199652>

Submitted on 7 Sep 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



ARTICLE

GenIDA, a participatory patient registry for genetic forms of intellectual disability provides detailed caregiver-reported information on 237 individuals with Koolen-de Vries syndrome



ARTICLE INFO

Article history:

Received 4 April 2023

Received in revised form

3 May 2023

Accepted 4 May 2023

Available online 18 May 2023

Keywords:

GenIDA

Intellectual disability

Koolen-de Vries syndrome

Neurodevelopmental disorders

Patient registry

ABSTRACT

Purpose: GenIDA is an international patient registry for individuals diagnosed with intellectual disability, autism spectrum disorder, and/or epilepsy, which is based on an online questionnaire that is completed by parent caregivers. In this study, the GenIDA data on Koolen-de Vries syndrome (KdVS) was analyzed illustrating the value of GenIDA and patient/caregiver participation in rare genetic neurodevelopmental disorders (NDDs).

Methods: Recruitment was done on the GenIDA website from November 2016 to February 2022. Clinical information on individuals with KdVS was extracted for in-depth analysis and for comparison with the GenIDA data of individuals diagnosed with other NDDs.

Results: A total of 1417 patients/caregivers across 35 genetic conditions answered to the GenIDA questionnaire, including caregivers of 237 individuals with KdVS. GenIDA findings on KdVS were consistent with the existing literature, and there were no significant differences between individuals with a 17q21.31 microdeletion and those with a pathogenic variant in the *KANSL1* gene. GenIDA provided detailed clinical information including features that are over-represented in KdVS compared with other NDDs (eg, laryngomalacia). Modeling of the natural history showed a positive development of speech and language over time and relatively good reading ability in KdVS. Valproate and oxcarbazepine were reported as effective antiepileptic drugs, and responses to open-ended questions indicated that childhood recurrent pneumonia and asthma are clinically relevant comorbidities that were not described in KdVS before.

Conclusion: GenIDA is a powerful registry to collect and harness valuable data on rare NDDs. The study shows that caregiver-driven data collection is effective in terms of global recruitment and centralization of clinical data.

© 2023 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The Article Publishing Charge (APC) for this article was paid by Jean-Louis Mandel.

Florent Colin and Pauline Burger contributed equally as co-first authors.

David A. Koolen and Jean-Louis Mandel contributed equally to this work.

*Correspondence and requests for materials should be addressed to Pauline Burger, Institute of Genetics and Molecular and Cellular Biology, Université de Strasbourg, INSERM U1258, CNRS UMR7104, 67400 Illkirch, France. *Email address:* burgerp@igbmc.fr OR David A. Koolen, Department of Human Genetics, Donders Institute for Brain, Cognition and Behavior, Radboud university medical center, Nijmegen, The Netherlands. *Email address:* david.koolen@radboudumc.nl OR Jean-Louis Mandel, Institute of Genetics and Molecular and Cellular Biology (IGBMC), Université de Strasbourg, INSERM U1258, CNRS UMR7104, Illkirch, France. *Email address:* jlmandel@igbmc.fr

A full list of authors and affiliations appears at the end of the paper.

doi: <https://doi.org/10.1016/j.gimo.2023.100817>

2949-7744/© 2023 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

GenIDA is a global patient registry for individuals diagnosed with genetic forms of intellectual disability (ID), with or without autism spectrum disorder (ASD) and/or epilepsy (<https://genida.unistra.fr/>).¹ Data on clinical features, comorbidities, progression over time, and responses to treatments are entered and updated by parents and other caregivers via a structured online questionnaire maximizing the enormous potential of their experience with these conditions.

Neurodevelopmental disorders (NDDs), including ID and ASD, affect approximately 2% of the population² and are characterized by a wide clinical and genetic variability. Advances in sequencing techniques have improved the diagnostic yield in clinical practice for individuals with NDDs in the past decade³ showing that de novo variants are key contributors to such disorders.⁴⁻⁸ There is an ever-growing list of up to 1500 genes or recurrent copy number variants (CNVs) involved in NDDs,⁹⁻¹¹ corresponding to an equivalent number of rare and distinct conditions. For many of these conditions, the knowledge of the clinical spectrum and natural history is limited, though this information is essential for the medical management of individuals diagnosed with an NDD and for addressing the legitimate concerns of parents and families.¹² GenIDA was launched in 2016 to address these knowledge gaps. Caregivers can fill out a structured questionnaire that is available in 8 languages (French, English, Dutch, German, Spanish, Italian, Portuguese, and Greek) and contains 5 numerical questions, 36 multiple-choice questions (MCQs) and their 92 subquestions, and 5 additional open-ended questions.¹ The data are visualized online by numerical graphs, and natural history for specific features is modeled by cross-sectional data from individuals at different ages. By February 2022, the GenIDA registry contained >71,200 answers to questions in the survey, providing clinical information on an international cohort of 1417 individuals diagnosed with an NDD associated with >35 different genes or CNVs ([Supplemental Figure 1](#)).

In this study, the data on 237 individuals with Koolen-de Vries syndrome (KdVS, OMIM 610443), the largest cohort in the registry, were analyzed. KdVS is a rare, multisystem NDD, which presents notably with hypotonia, developmental delay, mild to moderate ID, speech and language disorder, epilepsy, characteristic facial features, musculoskeletal anomalies, congenital heart anomalies, and urogenital malformations.¹³⁻¹⁷ The syndrome can be caused by a deletion of 17q21.31 that includes the *KANSL1* gene or by a heterozygous intragenic pathogenic variant in *KANSL1*.¹⁸⁻²¹ To our knowledge, this study is (by far) the largest clinical study to research KdVS and the first to use a data set solely built by caregivers. The study shows that GenIDA data are reliable and valuable and can provide useful knowledge about KdVS and rare genetic NDDs in general.

Materials and Methods

GenIDA

The setup and design of the GenIDA registry, including ethical approval, confidentiality, and the registration/recruitment process, are described in Burger et al.¹ Mandatory information is collected during the online registration procedure on the individual with the NDD and on the participating parent/caregiver. The mandatory information includes the name of the gene or CNV causing the NDD without specification of the exact pathogenic variant or duplication/deletion borders because this is potentially identifying information. No copy of the genetic report is required because this would raise issues of potential patient identification (GenIDA does not have the authorization to collect such data). The full online questionnaire can be found in [Supplemental Material 1](#), and daily operational aspects are described in [Supplemental Material 2](#). The recruitment of individuals with KdVS in the current study was international ([Supplemental Figure 2](#)). Recruitment was launched in November 2015 for a year-long beta testing period during which voluntary families were included to test the website features. Open recruitment was done exclusively on the GenIDA website after November 2016. In February 2022, KdVS data from the questionnaire, along with demographic information collected at registration, were locked and extracted for in-depth analysis.

Curation process and data analysis

To maximize data quality, 6 steps of curation were performed: (1) check for double accounts, (2) check for fake and empty or very low participating (<10 answers) accounts, (3) curation for wrong “year of birth” (because some caregivers were confused during registration and specified their own year of birth), (4) re-contact with caregivers when the genetic cause was unclear (eg, both 17q21.31 deletion and a *KANSL1* pathogenic variant reported), and (5) data refilling for lower participation (>8 to 30 responses) was done using the answers to the 5 open-ended questions (which some families filled in exhaustively) and moving them to the appropriate MCQ, and (6) broad curation of numerical data to remove mistakes (eg, wrong units for weight/height).

Caregivers are encouraged to update data on a regular basis (preferably annually). Approximately 10% of the KdVS records are updated per year, generally describing the occurrence of a novel clinical feature or adverse drug reaction ([Supplemental Figure 3](#)).

Statistical analyses of MCQs and numerical data included means, standard deviations, percentages, and absolute values/sizes for quantifiable items (ie, comorbidities reported through MCQs). The analysis and construction of

the graphs were done according to the nature of the data collected²²:

- In case of cross-sectional data (collected at a single point in time), only the most recent data concerning a given individual were used for data analysis because parent caregivers can actualize their answers over time. It should, however, be stressed that all serial responses for a given individual were conserved in the database and can be found in the corresponding individual PDF file.
- In case of data collected for different age groups (0-2, >2-4, >6-13, >13-19, or >19 years), each group was treated individually, meaning that if a caregiver responded multiple times to the survey (ie, when the child was 1, 4, and 8), the answers were used in the relevant age group of the graph. If the caregiver responded multiple times for a single age group (ie, when the child was 6, 7, and 8), only the most recent data were used in the analysis for the given age group.

Comparison between cohorts included frequencies, calculation of ratios, and nominal χ^2 test-based *P* value calculation, corrected for multiple testing. Textual data mining was done manually. For cohorts' comparisons, the answers to MCQs ("Yes"/"No") were extracted excluding the "I don't know" answers (Supplemental Figure 4, Supplemental Tables 1 and 2). Unless specified in captions, frequencies for subquestions were based on the total number of individuals for whom answers ("Yes"/"No") were available at the corresponding main question.

In the KdVS cohort, the majority of participants (>75%) was French, English, or Dutch speaking (Supplemental Figure 2), and their textual responses were analyzed and interpreted by one of the co-authors of this article in whose native language the answers were written. The other subset of answers was analyzed using the free version of the DeepL software (<https://www.deepl.com/translator/>). To remove inconsistencies in some translations, clinicians and researchers who participated in the specific analysis of the data were asked to provide input.

Results

Overview and validation of GenIDA clinical data on KdVS

In total, information on 237 KdVS individuals was documented in GenIDA by February 2022 (Supplemental Figure 2). The most represented countries are the United States (42.1%), followed by France (13.2%), Australia (7.9%), The Netherlands (7.9%), the United Kingdom (7.0%), and Germany (5.4%) (Supplemental Figure 2A). The cohort includes 116 males and 121 females (mean age 14.0 years; 1.8-47.6 years). In total, 197 persons had KdVS

because of the 17q21.31 deletion, and 40 persons had a *KANSL1* pathogenic variant (Supplemental Figure 2B). The survey was fully completed in 54.0%, and at least half of the questions were answered for 90.7% of the individuals with KdVS (Supplemental Figure 2C).

The most commonly reported clinical features in the KdVS cohort are summarized in Table 1 showing 36 different clinical features divided into 10 categories or organ systems. Comparison of the data with data from 2 previous KdVS cohort studies^{20,21} for major "Yes/No" MCQs yielded no significant differences (χ^2 tests with 2 degrees of freedom; Supplemental Figure 4).

Genotype phenotype correlation

Comparison of the full data set containing 196 clinical items between the individuals with a 17q21.31 microdeletion and those with a pathogenic variant in *KANSL1* did not reveal significant clinical differences according to the χ^2 test in agreement with previous observations²⁰ ($P < .00025$; Supplemental Table 1).

Clinical features overrepresented in the KdVS cohort

The reported frequencies of the clinical features in the KdVS cohort were compared with data from the other NDDs that were included in the GenIDA registry (Supplemental Table 2). Clinical features that were statistically more frequent ($P < .00025$) in KdVS compared with other NDDs in the registry included low amniotic fluid (3.8-fold), lack of fetal movement (3.3-fold), hypotonia at birth (2.9-fold), jaundice (2.5-fold), neonatal feeding difficulties (1.5-fold), atrial septal defect (2.5-fold), laryngomalacia (4.4-fold), tracheomalacia (5.2-fold), epilepsy (1.5-fold), joint laxity (2.1-fold), hip dysplasia (4.1-fold), high number of moles (5.6-fold), hypodontia (4.8-fold), and good reading ability (1.7-fold). Interestingly, behavioral problems were significantly less common in KdVS compared with the GenIDA data in general, according to the χ^2 test (0.8-fold).

A summary of the main KdVS features and systems involved is given below. The reported clinical features in the KdVS cohort are summarized in Table 1, and details and answers to subquestions are shown in Supplemental Table 2.

Prenatal and neonatal history

Problems during pregnancy, labor, and/or delivery were common in KdVS (77.9%) and mainly included low amniotic fluid (17.2%), reduced fetal movement (19.9%), or lack of fetal movement (14.5%). Abnormal ultrasound results were reported in 22.0% of the cases. The proportion of cesarean deliveries (53.2%) was twice as high as in the general population²³ (Figure 1A). At birth, on average, the

Table 1 Most reported clinical features for KdVS in GenIDA

Clinical Features	Yes	Total	%
Prenatal and neonatal history			
Low amniotic fluid	32	213	15.0
Cesarean section	99	213	46.5
Abnormal ultrasound results	41	213	19.2
Jaundice	109	226	48.2
Signs of anoxia	35	226	15.5
Hypotonia	139	226	61.5
Feeding difficulties	136	226	60.2
Psychomotor development			
Fine motor problems, clumsiness	68	162	42.0
Walking problems (children older than 2 y)	60	153	39.2
Speech and language delay (children older than 2 y)	128	174	73.6
Diagnosis of intellectual disability (children older than 6 y)	165	185	89.2
Neurologic and psychiatric features			
Epilepsy	97	204	47.5
Behavioral problems	109	199	54.8
Vision and hearing			
Hypermetropia	76	196	38.8
Strabismus	68	196	34.7
Hearing impairment	24	196	12.2
Recurrent ear infections	34	196	17.3
Cardiovascular system			
Atrial septal defect	81	201	40.3
Ventricular septal defect	38	201	18.9
Respiratory and pulmonary system			
Asthma	80	201	39.8
Laryngomalacia	33	201	16.4
Tracheomalacia	31	201	15.4
Digestive/excretory system			
Swallowing difficulties	17	201	8.5
Hypersalivation	23	143	16.1
Constipation	39	143	27.3
Urogenital system			
Renal/kidney, bladder, and urogenital system problems	60	193	31.1
Musculoskeletal system			
Renal/kidney, bladder, and urogenital system problems	74	193	38.3
Joint laxity	151	200	75.5
Hip dysplasia	100	200	50.0
Pes planus	36	200	18.0
Scoliosis	44	200	22.0
Miscellaneous			
Sleeping disorders	51	200	25.5
Skin, nail, and hair problems	75	176	42.6
High number of moles	104	201	51.7
Dental problems	44	201	21.9
Endocrine and metabolic systems' problems	112	172	65.1
Blood and immune system problems	31	177	17.5
	88	206	42.7

All "I don't know" answers were excluded; data collection period: November 2016 to February 2022.

Apgar scores at 1, 5, and 10 minutes were 7, 9, and 9, respectively. At 1 minute, the Apgar score was below 6 in 25% of the individuals with KdVS (first quartile) (Figure 1B). The neonatal period was complicated in 86.4%, including neonatal hypotonia (62.9%), feeding difficulties (61.5%), and jaundice (49.3%) (Figure 1C).

Psychomotor development

The developmental motor milestones in KdVS were delayed when compared with the median of the World Health Organization²⁴: ability to sit without support at 10.7 months (vs 6 months), to stand without support at 17.5 months (vs 11 months), and to walk without support at 23.4 months (vs 12 months) (Figure 1D). Fine motor problems or clumsiness was reported for 42.0% of the individuals with KdVS (Supplemental Table 2). The onset of first words was delayed by more than 12 months (average onset of words at 2.2 years) compared with typical development (Figure 2A). Interestingly, speech ability increased over time as >43.8% (14 of 32) of the individuals with KdVS >13 years of age were able to use full and correct sentences (Figure 2B). Most individuals with KdVS who were older than 6 years (95.4%) could be understood by the family, whereas 48.1% could be understood by people outside the direct family circle, confirming previous studies on speech and language impairment in KdVS.^{16,25} To evaluate the specificity of these findings, a similar analysis was performed on 2 other cohorts in GenIDA, that is, the Kleefstra syndrome (KS) (male/female 47%/53%; mean age 13.9 years) and KBG syndrome (KBGS) (male/female 61%/39%; mean age 14.4 years). The age of first words and understandability were similar for KdVS and KS (Figure 2A and C), whereas compared with KBGS, the "age of first words" is higher in KdVS (average 2.2 years, $n = 139$ vs average 1.6 years, $n = 35$), and "understandability by strangers" is reduced (48.1%, $n = 108$ vs 61.5%, $n = 26$) (Figure 2C).

A favorable evolution of reading ability was observed over time because 20 of 31 individuals with KdVS who were older than 13 years had good reading skills. Writing skills were limited even at a later age because only 6 of 30 persons older than 13 years had good writing ability according to their caregivers. In 89.2% of the individuals with KdVS who were older than 6 years, a formal diagnosis of ID was made (mild 16.9%, moderate 60.2%, severe 2.4%, and profound 20.5%). Many individuals with KdVS who were older than 6 years were able to dress themselves (89.4%), brush their teeth (82.1%), actively assist with personal care (90.2%), but they were considerably less capable to tie their shoelaces (21.2%) (Supplemental Table 2). Children older than 5 years had special educational needs in 85.1% of the cases.

Neurological and psychiatric features

Epilepsy

Epilepsy was present in 47.3% of individuals with KdVS (Figure 3A), which is in line with data from the medical literature.^{20,21} Seizure types reported the most were tonic-clonic seizures (37 of 97, 38.1%), absence seizures (28 of 97, 28.9%), and complex partial seizures (eg, focal impaired awareness seizures, 22 of 97, 22.7%). The average age at the first seizure was 3.4 years, with a median of 2.0 years (Figure 3B), supporting the findings in a previous study on 31




Figure 1 Pregnancy, newborn, and early life problems (data collection period: November 2016-February 2022). A. Frequencies of issues/complications during pregnancy, labor, and delivery for individuals with KdVS and their mother (percentages were calculated for those with a reported problem, ie, response = “Yes”). B. Apgar scores at 1, 5, and 10 minutes. C. Frequencies of newborn issues. D. Developmental milestones in months (sitting, standing, or walking alone). For comparison, medians from the World Health Organization are indicated in the table in brackets.²⁴ KdVS, Koolen-de Vries syndrome.

individuals with KdVS along with epilepsy.²⁶ Multiple reports of adverse effect of antiepileptic drug treatment in the open answers’ fields for the individuals with KdVS prompted us to perform an additional analysis on the perceived efficacy of the treatments by drugs and the frequency of adverse events for each (data freeze: November 2016-August 2019; Figure 3C). Of the 81 individuals with KdVS along with epilepsy, 14 reported no medication as the epilepsy spontaneously resolved or seizures were rare enough that treatment was not initiated. There was no information regarding the specific medications used for an additional 13 individuals with KdVS. The drugs used most frequently were

levetiracetam (30 of 54), valproate (24 of 54), and oxcarbazepine (13 of 54), with perceived efficacy ranging from 67% to 85%. Reports of significant adverse events were relatively rare for oxcarbazepine (1 of 13, 8.0%), but higher for levetiracetam (14 of 30, 47.0%) and valproate (7 of 24, 29.0%; 3 additional individuals reported mild secondary events). Four major adverse events were reported: (1) severe behavioral changes with levetiracetam, (2) Stevens-Johnson syndrome with carbamazepine, (3) Cushing syndrome and mood change with adrenocorticotrophic hormone, and (4) respiratory distress requiring hospitalization with combined diazepam and clonazepam treatment.




Figure 2 Speech ability (data collection period: November 2016-February 2022). A. Reported age at first word in years for individuals with KdVS (male/female 49%/51%; mean age 14.0 years) compared with individuals with Kleefstra (male/female 47%/53%; mean age 13.9 years) and KBG syndrome (male/female 61%/39%; mean age 14.4 years), respectively. B. Speech ability for individuals with KdVS (age ≥ 2 years) as reported by families. The 25% and 50% thresholds for “full correct sentences” are indicated by arrows in the longitudinal representation (below): 10% of the data points derived from answers concerning a given individual diagnosed with an NDD at 2 age ranges. C. Reported understandability (age ≥ 6 years) of individuals diagnosed with a NDD by family members and by strangers. KdVS, Koolen-de Vries syndrome; KBGS, KBG syndrome; KS, Kleefstra syndrome; NDD, neurodevelopmental disorder.

Behavioral problems

The frequency of behavioral problems was reported across 13 subquestions. The most frequent behavioral problems reported for KdVS were repetitive behavior/stereotypes (35.2%), attention deficit (32.7%), anxiety (31.2%), obsessive behavior (29.6%), and hyperactivity (27.6%). Attention deficit was rated most frequently as a major problem (Figure 4A).

Overall, individuals with KdVS (>6 years of age) were described as average to highly sociable with familiar children in 88.6% and in 98.1% with familiar adults. The individuals in the KdVS cohort were less likely to experience behavioral problems compared with other individuals with NDDs (odds ratio 0.8; Supplemental Table 1), and behavioral problems were also reported less frequently in KdVS (54.8%) compared with KS and KBGS, 2 other specific NDDs for which sufficient data were available (71.4% and 83.7%, respectively) (Figure 4B).

Vision and hearing

Hypermetropia is present in 38.8% of individuals in the GenIDA KdVS cohort, and strabismus was reported in 34.7% (Supplemental Table 2). Other clinical features involving the eyes were nystagmus (4.6%) and 4 cases of infantile cataract (2.0%). Hearing problems (40.8%) mainly

included deafness (12.2%) and recurrent ear infections (17.3%).

Cardiovascular

Congenital heart anomalies in the KdVS cohort mainly included atrial septal defect (18.9%) or ventricular septal defect (10.9%), but other cardiac anomalies were also reported, including bicuspid aortic valve, cardiomyopathy, pulmonary stenosis, broadening of the aorta/aorta root, patent ductus arteriosus, tetralogy of Fallot, and cardiac rhythm problems (Supplemental Table 2).

Respiratory and pulmonary system

In the open questions of the GenIDA questionnaire, respiratory problems were reported as one of the major medical problems that affect the persons' health and quality of life. Overall, respiratory problems were reported in 39.8% (80 of 201) of the individuals with KdVS (Figure 5A). Tracheomalacia (17 of 201, 8.5%) and laryngomalacia (31 of 201, 15.4%) were reported previously,^{20,21} but the relatively high frequency of respiratory infections was unknown. There was no MCQ subquestion on pulmonary respiratory infections and these problems were self-reported by the caregivers in the open-ended questions (Figure 5B). They often reported




Figure 3 Epilepsy (seizures) in KdVS (data collection period: November 2016-February 2022). A. Frequency of epilepsy in individuals with KdVS ($n = 204$) and reported types of seizures and their perceived severity (percentages were calculated as follows: number of events reported [major + moderate + minor] / number of individuals who answered “yes” to the question “Epilepsy,” ie, $n = 97$). B. Age at first seizure (age of onset) compared with current age of 80 well-described epileptic individuals with KdVS. C. Summary of drugs’ use, perceived efficacy, and corresponding frequencies of adverse events (percentages were calculated only when drug use was reported for at least 5 persons). (Anterior data freeze [November 2016-August 2019]: “no medication” was reported for 14 persons [because epilepsy resolved on its own] or mentioned only “sporadic events”; treatments were not specified for 13 persons who were thus excluded from the table) (see also examples of open text answers in Supplemental Material 4). KdVS, Koolen-de Vries syndrome.




Figure 4 Behavioral problems and their perceived severity in KdVS and comparison with KS and KBGS (data collection period: November 2016-February 2022). A. Frequencies of various behavioral problems in individuals with KdVS and their perceived severity (percentages were calculated as follows: number of events reported [major + moderate + minor event] / number of individuals who answered to the question “behavior problem,” ie, $n = 199$). B. Overall frequencies of behavioral problems reported for individuals with KdVS, KS, and KBG. KBGS, KBG syndrome; KdVS, Koolen-de Vries syndrome; KS, Kleefstra syndrome.

“croup” or “chest infection” without further specification, and notably cited pneumonia, a condition described as recurrent in 13 persons and often leading to hospitalization. Pneumonia was generally of bacterial or viral origin with 2 reported cases of “aspiration” pneumonia. In the majority, the first pneumonia occurred within the first 18 months (average 15.5 months), and most did not have pneumonia after age 10 though some still had pneumonia in adolescence or adulthood (latest event on average 8.4 years) (Figure 5C). Other reported respiratory problems included asthma (33 of 201, 16.4%). In 12 cases, caregivers also reported immune system problems, including lymphopenia, neutropenia, common variable immune deficiencies, and IgG deficiencies.

Gastrointestinal tract and urogenital system

The most frequently reported clinical feature of the gastrointestinal tract in the KdVS cohort was constipation (31.1%)

followed by hypersalivation (27.3%) and swallowing difficulties (16.1%; Supplemental Table 2). Regurgitation (7.8%), repeated vomiting episodes (8.3%), and diarrhea (8.8%) were also reported. Renal and urogenital anomalies were present in 38.3%. Cryptorchidism was present in 22.6% of the male individuals with KdVS. Other important anomalies of the urogenital tract included vesicoureteral reflux (6.2%), and recurrent urinary infections in 20.0% of the female individuals with KdVS and 3.2% of the male individuals with KdVS.

Musculoskeletal system

Musculoskeletal anomalies were present in 75.5%, including hypermobility (joint laxity, 50.0%), hip dislocation/dysplasia (18.0%), pes planus (22.0%), and scoliosis (25.5%; Supplemental Table 2). Other musculoskeletal problems were reported in less than 10.0%, for example, club feet (3.0%) and contractures (2.5%).




Figure 5 Respiratory problems reported by individuals with KdVS (data collection period: November 2016–February 2022). A. Types and frequencies of respiratory problems reported (laryngomalacia and tracheomalacia were the only manifestations previously reported in literature). B. Examples of open-ended answers reporting respiratory problems. C. Age at earliest and latest pneumonia events from well-documented individuals diagnosed with KdVS (data collected after re-contacting families). KdVS, Koolen-de Vries syndrome.

Miscellaneous

Skin, nail, and hair abnormalities were present in 51.7% of the cases, for example, multiple nevi (21.9%). Dental problems were reported in 65.1%. A detailed analysis of the orodental features is available in [Supplemental Material 3](#). It is of note that “tongue tie” (ankyloglossia) was mentioned by 7 families, which is relevant to address in the overall management of individuals with KdVS. In the responses to the open-ended questions, 4 cases of double cataract at a young age were reported and 4 cases of Hashimoto disease. Sleep problems occurred in approximately 42.6% of KdVS cases. There is no significant difference according to the χ^2 test ([Supplemental Table 2](#)) in the occurrence of sleep problems in KdVS compared to all other cohorts in GenIDA. Still, the high number of individuals with KdVS experiencing a sleep problem warrants follow-up analysis and research considering how interventions that improve sleep can be incorporated into KdVS health care management.

Discussion

Detailed and extensive clinical data

The GenIDA KdVS data analysis in this study shows that caregivers provide valuable information about KdVS and rare NDDs in general. They are motivated to complete a relatively long structured questionnaire and thereby contribute to research on rare NDDs. Parents are experts on their child and know him/her better than any health care professional. For rare diseases this is a huge source of information and GenIDA can play an important role in collecting and summarizing these data. The involvement of clinicians in such registries is essential to promote recruitment and conduct data analysis and interpretation. In this study, caregivers provided extensive clinical information by answering an extensive online questionnaire, allowing assessments on 196 items, with additional numeric and textual elements. The data are reliable as they give frequencies of phenotypes that are comparable to previously published observations from clinicians-driven

studies^{20,21} (Supplemental Figure 4), though it might be possible that data on some individuals are included in both GenIDA and one of the studies in the comparison.

Importantly, the GenIDA data set adds to the body of knowledge about KdVS and its management. The data are in many aspects much more extensive than previously published and the cohort is considerably larger than cohorts described in the medical literature.^{20,21} This allows new findings to be made but it also confirms previous findings in the smaller cohorts. Most answers to the questions and subquestions of the questionnaire concerning the KdVS cohort ($n = 237$) are presented in Figures 1 to 5 and in Supplemental Tables 1 and 2, with the exception of textual answers to open-ended questions. Only a sampling of the textual answers is presented for respiratory problems (Figure 5) and responses to antiepileptic treatments (Supplemental Material 4). These data provide an overview of the clinical spectrum of the syndrome, which is valuable in daily clinical practice. Many doctors caring for a child with KdVS have only little experience with this rare condition and this information can help them to counsel families and provide appropriate care for the patient.

No significant genotype phenotype relation

The current data set contains 197 persons diagnosed with KdVS because of a 17q21.31 deletion and 40 persons with a pathogenic *KANSL1* variant. Comparison of the full data set between these 2 groups did not show significant clinical differences according to the χ^2 test (Supplemental Table 1), which is in agreement with previous observations,²⁰ stressing the previous conclusion that haploinsufficiency of *KANSL1* is sufficient to cause the core phenotype of KdVS.^{18,19}

Clinical features that are overrepresented compared with other NDDs

Comparison of the KdVS data with the overall GenIDA data shows clinical features that are significantly more frequent in KdVS according to the χ^2 test (Supplemental Table 2). This demonstrates an interesting potential for GenIDA because many clinical features in individuals with NDD are relatively unspecific, such as hypotonia, developmental delay, or constipation. This type of comparison may reveal clinical features that require extra attention in a specific condition. Clinical features that were statistically more frequent (P -value $< .00025$) in KdVS compared with other NDDs mainly include clinical signs in the perinatal period, such as low amniotic fluid, lack of fetal movement, hypotonia at birth, and neonatal feeding difficulties. Atrial septal defect and epilepsy are also reported more often. There is a >4 -fold greater odds of tracheomalacia/laryngomalacia for KdVS than for other NDDs, stressing the importance of upper airway evaluation in infants and children with KdVS and signs or symptoms suspicious of tracheomalacia/laryngomalacia.

A high number of moles is also reported more often (5.6-fold). This is something specific to look for at physical examination and individuals with KdVS who have multiple naevi or a skin type that is at greater risk for developing melanoma should be evaluated periodically to assess ectodermal findings and cutaneous changes.

Modeled natural history

A great potential value of GenIDA is the collection of longitudinal data on KdVS and other rare NDDs. This is important not only for counseling but also for determining outcome measures for possible treatment and interventions. Clinical information on individual patients at different time points is still limited, but cross-sectional data from individuals diagnosed with KdVS of different ages allowed the modeling of the natural history of 4 important aspects of NDDs: speech, language, reading, and writing ability. The results regarding speech and language in KdVS were encouraging: children continued to develop verbal speech and language after the delayed onset of first words, with the majority of respondents noting that children could speak using well-formed sentences as teenagers. Yet, the clarity of speech or “understandability” of individuals with KdVS (Figure 2) was significantly reduced, with only 48.1% of the persons >6 years of age that could be understood by strangers. These findings are in line with detailed speech and language phenotyping studies of children with KdVS that used standardized assessments, which also show a high percentage of speech production disorders associated with poor speech intelligibility.^{16,25} Writing skills appear limited even at a later age and could be affected by the fine motor skills problems reported in the KdVS (42.0%), a finding that is again in line with the previous phenotyped cohorts.^{16,25}

Information on adverse effects of drugs

For epilepsy, GenIDA confirms earlier data based on smaller cohorts with respect to the proportion of KdVS individuals with epilepsy.²⁶ GenIDA also shows data on the perceived efficacy of drugs and information on their adverse effects, stressing that the open answers from caregivers are a rich source of information (Figure 3, Supplemental Material 4). Based on the current data, it might be cautiously suggested that valproate and oxcarbazepine (the latter used less often) exhibit better efficacy and lower adverse effects than levetiracetam, a trend already noted by Myers et al²⁶ in a smaller cohort.

Clinical features that were previously not been reported

Importantly, clinical problems were identified that were previously not been reported in KdVS studies, such as childhood respiratory disorders, including recurrent pneumonia and childhood asthma, affecting about 40% of individuals with KdVS (Figure 5). These features were often perceived as a

major health concern by caregivers, based on the open text answers (Figure 5). Children with neurocognitive impairment often present with chronic or recurrent respiratory problems, which can have an important impact on the quality of life. Possible underlying causes are risk of aspiration, insufficient cough, upper airway obstruction, and progressive kyphoscoliosis.^{27,28} Other contributing factors might be an impaired immune response (which is reported by some caregivers). It is of interest that GWAS have identified an association of the *KANSL1* locus with parameters of lung functions.²⁹⁻³¹

Limitations of GenIDA

Some caregivers indicated that the online questionnaire took too long to complete, which, in turn, might have resulted in higher drop-off rates. In addition, some GenIDA users encountered problems resulting from poor website ergonomics, mainly in the process of registration and in answering the survey questions. The GenIDA study also faces the limitations inherent in questionnaire studies, including recall bias, missing responses, and variable personal interpretation of questions by respondents.

Conclusion

The analysis of GenIDA information on 237 individuals with KdVS shows that caregiver-driven data collection is an approach that is effective in terms of both global recruitment and centralization of clinical data in rare NDDs. The caregiver derived data are in line with previous KdVS cohort studies, and there was no significant genotype-phenotype relation (CNV deletion vs *KANSL1* pathogenic variant). Comparison of the KdVS cohort with other NDD cohorts in the registry revealed clinical features that are over-represented in the KdVS cohort, including tracheomalacia/laryngomalacia. Modeling of natural history showed a positive development of speech and language over time and relatively good reading ability. In case of epilepsy, valproate and oxcarbazepine were reported as effective antiepileptic drugs, whereas levetiracetam may have a relative lack of efficacy. Finally, childhood respiratory disorders, including recurrent pneumonia, is a group of novel clinical conditions that was not reported in KdVS before.

In conclusion, GenIDA is a powerful registry to collect and harness valuable data on rare NDDs, which is essential for genetic counseling, clinical decision making, and determining clinical outcome measures. The registry may serve as a starting point for follow-up research into the clinically relevant observations, which might result in better management and personalized treatment strategies in NDDs.

Data Availability

Data specific to a cohort of individuals diagnosed with an NDD in GenIDA are accessible in processed form via the

visualization tab (<https://genida.unistra.fr/visualizations/>), item by item, on the website to any caregiver registered in GenIDA in the said cohort (<https://genida.unistra.fr/register/>), as soon as the threshold of 10 completed files for the said condition is reached (defined for statistical analysis). They are also available to any professional user upon simple registration in GenIDA.

Each participating caregiver can download its relevant PDF file, sort of anonymous clinical records containing all questionnaire responses for a single individual diagnosed with an NDD.

Registered investigators/professionals wishing to have access to these PDFs must justify their request (short statement explaining their project) to the GenIDA administration by email (genida@igbmc.fr) and commit to respecting the confidentiality of the study participants and therefore not to disseminate the PDFs.

Acknowledgments

The authors thank the Institute for Advanced Studies of the University of Strasbourg (USIAS), the University of Strasbourg Foundation (Roche Fund for Personalized Medicine), and the Fondation Jérôme Lejeune and the National Research Network “Groupement d’Intérêt Scientifique Autisme et Troubles du Neuro-Développement” (GIS Autisme et TND) for their financial support.

The GenIDA project is supported by the French RaDiCo (Rare Disease Cohorts) research program for national and European cohorts of patients with rare diseases. This work is generated within the European Reference Network for Intellectual disability, TeleHealth, Autism and Congenital Anomalies (ERN ITHACA). The authors also thank Doulaye Dembele, Genomeast, IGBMC, for his help in the statistical analysis of the GenIDA data. Finally, the authors thank all the GenIDA participants and the patients’ associations (and notably <https://supportingkdvs.org/>; <http://www.koolkidalliance.com/>; <https://www.koolendevriesfrance.org/>).

Funding

This research was funded by the Institute for Advanced Studies of the University of Strasbourg (USIAS), the University of Strasbourg Foundation (Roche Fund for Personalized Medicine), the Fondation Jérôme Lejeune, and the GIS “Autisme & TND”.

Author Information

Conceptualization: F.C., T.M., T.K., P.P., D.A.K., J.-L.M.; Data Curation: F.C., P.B., J.-L.M., Formal Analysis: F.C., P.B., J.K., N.C., E.B., J.-L.M.; Funding Acquisition: F.C., P.B., J.-L.M.; Investigation: F.C., P.B., J.K., J.-L.M.; Project Administration: F.C., P.B., A.S., J.-L.M.; Software (Design and development of the registry and confidentiality

model): T.M., P.P.; Supervision: J.-L.M.; Visualization: F.C., T.M., J.-L.M.; Writing-original draft: F.C., P.B., J.K., N.C., T.K., D.A.K., J.-L.M.; Writing-review and editing: F.C., P.B., J.K., N.C., A.T.M., K.A.M., A.B.-Z., C.W.O., B.B.A.d.V., T.K., P.P., D.A.K., J.-L.M.

ORCIDs

Florent Colin: <http://orcid.org/0000-0002-0527-2879>
 Pauline Burger: <http://orcid.org/0000-0003-2109-5451>
 Timothée Mazzucotelli: <http://orcid.org/0000-0003-1282-5088>
 Joost Kummeling: <http://orcid.org/0000-0003-4870-0666>
 Elyette Broly: <http://orcid.org/0000-0001-9065-4697>
 Angela T. Morgan: <http://orcid.org/0000-0002-1117-8782>
 Kenneth A. Myers: <http://orcid.org/0000-0001-7831-4593>
 Agnès Bloch-Zupan: <http://orcid.org/0000-0002-6511-2615>
 Charlotte W. Ockeloen: <http://orcid.org/0000-0003-0329-1520>
 Bert B.A. de Vries: <http://orcid.org/0000-0002-0000-2917>
 Tjitske Kleefstra: <http://orcid.org/0000-0002-0956-0237>
 Pierre Parrend: <http://orcid.org/0000-0002-1680-1182>
 David A. Koolen: <http://orcid.org/0000-0002-2152-4626>
 Jean-Louis Mandel: <http://orcid.org/0000-0002-0535-6589>

Ethics Declaration

GenIDA satisfies all ethical requirements: the research is carried out in accordance with the provisions of the French Data Protection Act (French law of January 6, 1978, amended by the law of August 6, 2004, on the protection of individuals with regard to the processing of personal data), and complies with the General Data Protection Regulation 2016/679 (GDPR). The study has been declared to the French “Commission Nationale Informatique et Libertés” (CNIL) on November 27, 2015, number 1907912v0. It has been reviewed and approved by the Ethics Evaluation Committee (IORG0003254, FWA00005831), the Institutional Review Board (IRB00003888) of the French Institute of Medical Research and Health on November 15, 2016, number 16-338, and on September 4, 2019, number 16-338 bis. It was developed in collaboration with the French Rare Disease Cohort program (RaDiCo: <https://www.radico.fr/en/accueil>) and information security and data management specialist from ICube laboratory in Strasbourg (PP). Potential risks concerning data storage, security, privacy, type of data asked, or structure of the website have been considered during the development of this project and are detailed in the validated research protocol of the project (available on request).

Individuals registered to the study were asked to read the information note and give their informed consent during the registration, before accessing the questionnaire. Whether because of their age or their ability to participate, only a minority of people with ID participate in GenIDA on their

own behalf and therefore give their consent to participate in our study. In the vast majority of cases, it is the caregivers (usually the parents) who register and therefore give their consent to participate in the study. They are sole actors in the data submission process and have the right to edit and delete their answers. At any time and without any justification, they can withdraw his/her participation agreement.

Consent is not sought from the person for whom a record is completed, even in cases in which that person is classified as “without ID” or is diagnosed as having a mild ID or as not (yet) needing special education. Indeed, an individual listed as “without ID” may either not have an ID, may be borderline, or may not have been tested for IQ or other tests and thus not have a formal diagnosis at the time of participation in the study (especially children and youth who may be developmentally delayed but have not yet been formally tested, or adults who have not been formally tested or who were tested long ago but have forgotten the test results). In addition, most of the people with ID reported in GenIDA are minors (and may not yet need formal special education) and are still in their parents’ care. However, if a person for whom a file has been completed by a parent caregiver wishes to withdraw consent, he or she is fully entitled to ask us at any time to delete his or her record and answers that concern him or her.

Informed consent was obtained from all participants (primarily caregivers as well as 9 of 237 individuals with KdVS participating on their own behalf) enrolled to this specific Koolen-de Vries study as required. All of the data collected were deidentified. This research was conducted in accordance with the principles set out in the Declaration of Helsinki.

Conflict of Interest

The authors declare no conflicts of interest.

Additional Information

The online version of this article (<https://doi.org/10.1016/j.gimo.2023.100817>) contains supplemental material, which is available to authorized users.

Authors

Florent Colin^{1,2} , Pauline Burger^{1,*} ,
 Timothée Mazzucotelli¹ , Axelle Strehle¹,
 Joost Kummeling³ , Nicole Collot¹, Elyette Broly^{1,4,5} ,
 Angela T. Morgan^{6,7} , Kenneth A. Myers^{8,9,10} ,
 Agnès Bloch-Zupan^{1,4,5} , Charlotte W. Ockeloen³ ,
 Bert B.A. de Vries³ , Tjitske Kleefstra^{3,11,12} ,
 Pierre Parrend^{13,14} , David A. Koolen^{3,*} ,
 Jean-Louis Mandel^{1,15,*} 

Affiliations

¹Institute of Genetics and Molecular and Cellular Biology (IGBMC), Université de Strasbourg, INSERM U1258, CNRS UMR7104, Illkirch, France; ²INSERM UMR_S1109, Tumor Biomechanics Lab, University of Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France; ³Department of Human Genetics, Donders Institute for Brain, Cognition and Behavior, Radboud university medical center, Nijmegen, The Netherlands; ⁴Faculté de Chirurgie Dentaire, Université de Strasbourg, Strasbourg, France; ⁵Centre de référence des maladies rares orales et dentaires, O-Rares, Filière Santé Maladies rares Tête Cou, European Reference Network ERN CRANIO, Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg, France; ⁶Murdoch Children's Research Institute, Parkville, Australia; ⁷Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Melbourne, Australia; ⁸Department of Pediatrics, Montreal Children's Hospital, McGill University, Montreal, Quebec, Canada; ⁹Department of Neurology and Neurosurgery, Montreal Children's Hospital, McGill University, Montreal, Quebec, Canada; ¹⁰Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada; ¹¹Centre of Excellence for Neuropsychiatry, Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands; ¹²Department Clinical Genetics, Erasmus MC Rotterdam, The Netherlands; ¹³ICube laboratory (Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie), UMR 7357, Université de Strasbourg, CNRS, Strasbourg, France; ¹⁴EPITA, Strasbourg, France; ¹⁵University of Strasbourg Institute for Advanced Studies (USIAS), Strasbourg, France

References

- Burger P, Colin F, Strehle A, et al. GenIDA: an international participatory database to gain knowledge on health issues related to genetic forms of neurodevelopmental disorders. *J Neural Transm (Vienna)*. 2023;130(3):459-471. <http://doi.org/10.1007/s00702-022-02569-3>
- Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. *Res Dev Disabil*. 2011;32(2):419-436. <http://doi.org/10.1016/j.ridd.2010.12.018>
- Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. *Genet Med*. 2019;21(11):2413-2421. <http://doi.org/10.1038/s41436-019-0554-6>
- Iossifov I, O'Roak BJ, Sanders SJ, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature*. 2014;515(7526):216-221. <http://doi.org/10.1038/nature13908>
- Krumm N, Turner TN, Baker C, et al. Excess of rare, inherited truncating mutations in autism. *Nat Genet*. 2015;47(6):582-588. <http://doi.org/10.1038/ng.3303>
- Coe BP, Stessman HAF, Sulovari A, et al. Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. *Nat Genet*. 2019;51(1):106-116. <http://doi.org/10.1038/s41588-018-0288-4>
- Kaplanis J, Samocha KE, Wiel L, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. *Nature*. 2020;586(7831):757-762. <http://doi.org/10.1038/s41586-020-2832-5>
- Satterstrom FK, Kosmicki JA, Wang J, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *Cell*. 2020;180(3):568-584.e23. <http://doi.org/10.1016/j.cell.2019.12.036>
- Popp B, Ekici AB, Thiel CT, et al. Exome Pool-Seq in neurodevelopmental disorders. *Eur J Hum Genet*. 2017;25(12):1364-1376. <http://doi.org/10.1038/s41431-017-0022-1>
- Kochinke K, Zweier C, Nijhof B, et al. Systematic phenomics analysis deconvolutes genes mutated in intellectual disability into biologically coherent modules. *Am J Hum Genet*. 2016;98(1):149-164. <http://doi.org/10.1016/j.ajhg.2015.11.024>
- SysNDD database. SysNDD. Accessed September 7, 2022. <https://sysndd.dbmr.unibe.ch/>
- Garbade SF, Zielonka M, Komatsuzaki S, et al. Quantitative retrospective natural history modeling for orphan drug development. *J Inher Metab Dis*. 2021;44(1):99-109. <http://doi.org/10.1002/jimd.12304>
- Koolen DA, Vissers LELM, Pfundt R, et al. A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. *Nat Genet*. 2006;38(9):999-1001. <http://doi.org/10.1038/ng1853>
- Sharp AJ, Hansen S, Selzer RR, et al. Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. *Nat Genet*. 2006;38(9):1038-1042. <http://doi.org/10.1038/ng1862>
- Shaw-Smith C, Pittman AM, Willatt L, et al. Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. *Nat Genet*. 2006;38(9):1032-1037. <http://doi.org/10.1038/ng1858>
- Morgan AT, van Haften LV, van Hulst K, et al. Early speech development in Koolen de Vries syndrome limited by oral praxis and hypotonia. *Eur J Hum Genet*. 2018;26(1):75-84. <http://doi.org/10.1038/s41431-017-0035-9>
- Koolen DA, Morgan A, de Vries BB. Koolen-de Vries syndrome. Accessed March 23, 2022. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*®. 2010. <http://www.ncbi.nlm.nih.gov/books/NBK24676/>
- Koolen DA, Kramer JM, Neveling K, et al. Mutations in the chromatin modifier gene KANSL1 cause the 17q21.31 microdeletion syndrome. *Nat Genet*. 2012;44(6):639-641. <http://doi.org/10.1038/ng.2262>
- Zollino M, Orteschi D, Murdolo M, et al. Mutations in KANSL1 cause the 17q21.31 microdeletion syndrome phenotype. *Nat Genet*. 2012;44(6):636-638. <http://doi.org/10.1038/ng.2257>
- Zollino M, Marangi G, Ponzi E, et al. Intragenic KANSL1 mutations and chromosome 17q21.31 deletions: broadening the clinical spectrum and genotype-phenotype correlations in a large cohort of patients. *J Med Genet*. 2015;52(12):804-814. <http://doi.org/10.1136/jmedgenet-2015-103184>
- Koolen DA, Pfundt R, Linda K, et al. The Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdeletion versus a KANSL1 sequence variant. *Eur J Hum Genet*. 2016;24(5):652-659. <http://doi.org/10.1038/ejhg.2015.178>
- Cross-sectional vs. longitudinal studies. Institute for Work & Health. Accessed January 11, 2023. <https://www.iwh.on.ca/what-researchers-mean-by/cross-sectional-vs-longitudinal-studies>
- Boerma T, Ronsmans C, Melesse DY, et al. Global epidemiology of use of and disparities in caesarean sections. *Lancet*. 2018;392(10155):1341-1348. [http://doi.org/10.1016/S0140-6736\(18\)31928-7](http://doi.org/10.1016/S0140-6736(18)31928-7)
- WHO Multicentre Growth Reference Study Group. WHO Motor Development Study: windows of achievement for six gross motor development milestones. *Acta Paediatr Suppl*. 2006;450:86-95. <http://doi.org/10.1111/j.1651-2227.2006.tb02379.x>
- St John M, van Reyk O, Koolen DA, de Vries BBA, Amor DJ, Morgan AT. Expanding the speech and language phenotype in Koolen-de Vries syndrome: late onset and periodic stuttering a novel

- feature. *Eur J Hum Genet.* 2023;31(5):531-540. <http://doi.org/10.1038/s41431-022-01230-7>
26. Myers KA, Mandelstam SA, Ramantani G, et al. The epileptology of Koolen-de Vries syndrome: electro-clinico-radiologic findings in 31 patients. *Epilepsia.* 2017;58(6):1085-1094. <http://doi.org/10.1111/epi.13746>
27. Morgan AT, Dodrill P, Ward EC. Interventions for oropharyngeal dysphagia in children with neurological impairment. *Cochrane Database Syst Rev.* 2012;10:CD009456. <http://doi.org/10.1002/14651858.CD009456.pub2>
28. Proesmans M. Respiratory illness in children with disability: a serious problem? *Breathe (Sheff).* 2016;12(4):e97-e103. <http://doi.org/10.1183/20734735.017416>
29. Wain LV, Shrine N, Artigas MS, et al. Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. *Nat Genet.* 2017;49(3):416-425. <http://doi.org/10.1038/ng.3787>
30. Wain LV, Shrine N, Miller S, et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. *Lancet Respir Med.* 2015;3(10):769-781. [http://doi.org/10.1016/S2213-2600\(15\)00283-0](http://doi.org/10.1016/S2213-2600(15)00283-0)
31. Degenhardt F, Ellinghaus D, Juzenas S, et al. Detailed stratified GWAS analysis for severe COVID-19 in four European populations. *Hum Mol Genet.* 2022;31(23):3945-3966. <http://doi.org/10.1093/hmg/ddac158>